Clinical Scorecard: The Port Delivery System in the Paradigm
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular age-related macular degeneration (nAMD), center-involving diabetic macular edema (CI-DME), diabetic retinopathy (DR) |
| Key Mechanisms | Continuous drug delivery of ranibizumab via a surgically implanted reservoir |
| Target Population | Adults who have previously responded to at least 2 anti-VEGF injections |
| Care Setting | Ophthalmology clinics |
Key Highlights
- PDS provides continuous delivery of ranibizumab with refills every 24 to 36 weeks.
- Clinical trials show noninferior efficacy compared to monthly intravitreal injections.
- 95% of PDS patients did not require supplemental ranibizumab treatment.
- Improved patient preference due to reduced treatment frequency.
- Enhanced surgical techniques have reduced complications over time.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and retinal anatomy for nAMD, CI-DME, and DR.
Management
- Consider PDS for patients requiring long-term anti-VEGF therapy.
Monitoring & Follow-up
- Regular follow-up for vision changes and potential complications.
Risks
- Monitor for endophthalmitis and other surgical complications.
Patient & Prescribing Data
Adults with nAMD, CI-DME, and DR who have responded to prior anti-VEGF therapy.
PDS offers sustained therapeutic effects and may reduce the risk of vision loss over time.
Clinical Best Practices
- Implement meticulous surgical techniques to minimize complications.
- Educate patients on the benefits and risks of PDS.
- Monitor patients closely for signs of endophthalmitis.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.